269 related articles for article (PubMed ID: 26925841)
21. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922
[TBL] [Abstract][Full Text] [Related]
22. GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice.
Park JI; Powers JF; Tischler AS; Strock CJ; Ball DW; Nelkin BD
Exp Cell Res; 2005 Feb; 303(1):79-88. PubMed ID: 15572029
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
[TBL] [Abstract][Full Text] [Related]
24. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
Chai G; Liu N; Ma J; Li H; Oblinger JL; Prahalad AK; Gong M; Chang LS; Wallace M; Muir D; Guha A; Phipps RJ; Hock JM; Yu X
Cancer Sci; 2010 Sep; 101(9):1997-2004. PubMed ID: 20550523
[TBL] [Abstract][Full Text] [Related]
26.
Hayashi T; Desmeules P; Smith RS; Drilon A; Somwar R; Ladanyi M
Clin Cancer Res; 2018 Mar; 24(6):1436-1447. PubMed ID: 29127119
[No Abstract] [Full Text] [Related]
27. All-trans retinoic acid induces COX-2 and prostaglandin E2 synthesis in SH-SY5Y human neuroblastoma cells: involvement of retinoic acid receptors and extracellular-regulated kinase 1/2.
Alique M; Herrero JF; Lucio-Cazana FJ
J Neuroinflammation; 2007 Jan; 4():1. PubMed ID: 17204142
[TBL] [Abstract][Full Text] [Related]
28. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Mayes PA; Degenhardt YY; Wood A; Toporovskya Y; Diskin SJ; Haglund E; Moy C; Wooster R; Maris JM
Int J Cancer; 2013 Feb; 132(3):E149-57. PubMed ID: 22948716
[TBL] [Abstract][Full Text] [Related]
29. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.
Lock R; Ingraham R; Maertens O; Miller AL; Weledji N; Legius E; Konicek BM; Yan SC; Graff JR; Cichowski K
J Clin Invest; 2016 Jun; 126(6):2181-90. PubMed ID: 27159396
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the Notch target gene Hes-1 by TGFalpha induced Ras/MAPK signaling in human neuroblastoma cells.
Stockhausen MT; Sjölund J; Axelson H
Exp Cell Res; 2005 Oct; 310(1):218-28. PubMed ID: 16120441
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
32. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
33. Partially purified components of Nardostachys chinensis suppress melanin synthesis through ERK and Akt signaling pathway with cAMP down-regulation in B16F10 cells.
Jang JY; Kim HN; Kim YR; Choi WY; Choi YH; Shin HK; Choi BT
J Ethnopharmacol; 2011 Oct; 137(3):1207-14. PubMed ID: 21816215
[TBL] [Abstract][Full Text] [Related]
34. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
35. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
36. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
37. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly.
Tsai J; Qiu W; Kohen-Avramoglu R; Adeli K
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):211-8. PubMed ID: 17038630
[TBL] [Abstract][Full Text] [Related]
38. Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: profiling multiple targets of cancer kinase signaling.
Sandoval JA; Eppstein AC; Hoelz DJ; Klein PJ; Linebarger JH; Turner KE; Rescorla FJ; Hickey RJ; Malkas LH; Schmidt CM
J Surg Res; 2006 Jul; 134(1):61-7. PubMed ID: 16650873
[TBL] [Abstract][Full Text] [Related]
39. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Shapira S; Barkan B; Friedman E; Kloog Y; Stein R
Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025
[TBL] [Abstract][Full Text] [Related]
40. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
Scorsone K; Zhang L; Woodfield SE; Hicks J; Zage PE
Invest New Drugs; 2014 Oct; 32(5):815-24. PubMed ID: 24832869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]